Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Assets (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Non-Current Assets for 13 consecutive years, with $13.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 48.27% to $13.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $50.3 million, a 42.38% increase, with the full-year FY2025 number at $13.8 million, up 48.27% from a year prior.
  • Non-Current Assets was $13.8 million for Q4 2025 at Madrigal Pharmaceuticals, down from $15.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $15.8 million in Q3 2025 to a low of $866000.0 in Q2 2023.
  • A 5-year average of $5.3 million and a median of $2.2 million in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: tumbled 53.09% in 2023, then soared 830.83% in 2024.
  • Madrigal Pharmaceuticals' Non-Current Assets stood at $1.6 million in 2021, then fell by 27.0% to $1.2 million in 2022, then surged by 171.49% to $3.3 million in 2023, then soared by 185.36% to $9.3 million in 2024, then soared by 48.27% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Non-Current Assets are $13.8 million (Q4 2025), $15.8 million (Q3 2025), and $12.0 million (Q2 2025).